Immune recognition of human T-cell leukemia virus type-I (HTLV-I) by MHC-restricted cytotoxic T lymphocytes. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immune recognition of human T-cell leukemia virus type-I (HTLV-I) by MHC-restricted cytotoxic T lymphocytes.

Kitasato Arch Exp Med. 1992 Sep;65(2-3):79-85. Unique Identifier : AIDSLINE MED/93368109
Tanaka Y; Department of Immunology, School of Hygienic Sciences, Kitasato; University, Kanagawa, Japan.

Abstract: In our studies, it was demonstrated for the first time that HTLV-I gag and pX, and env and pX antigens are the target antigens recognized by CD8+ CTL in association with RT-1k and RT-1l class I antigens, respectively, in the rat system. Furthermore, the gag-expressing rVV and the env-expressing rVV were shown to have the potential to induce HTLV-I-specific CTL in WKA and LEW rats, respectively. These results suggest that, in general, HTLV-I structural and non-structural antigens can be recognized by CTL, and their immunogenicity for the induction of HTLV-I-specific CTL may be influenced by host MHC. Successful vaccination of mice against retrovirus tumorigenicity with the viral structural components has been demonstrated. As was the case with polyoma virus-induced tumors, utilization of rVV vectors containing HTLV-I genes for potential HTLV-I vaccines in humans may become possible if target antigens recognized by each recipient CTL can be identified prior to vaccination. Another vaccine candidate will be a synthetic peptide containing each CTL epitope. We are currently identifying the CTL epitopes, and recent results indicate that a major CTL epitope on the env-gene product is located between the env amino acids 101-112 (Tanaka et al., manuscript in preparation).
Keywords: Animal Cell Line, Transformed Histocompatibility Antigens/*IMMUNOLOGY Human HTLV-I/*IMMUNOLOGY HTLV-I Antigens/ANALYSIS T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Vaccinia Virus/IMMUNOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDanimalcellline,transformedhistocompatibilityantigens/KWDimmunologyhumanhtlv-i/KWDimmunologyhtlv-iantigens/analysist-lymphocytes,cytotoxic/KWDimmunologyvacciniavirus/immunologyjournalarticlereviewreview,tutorial
931230
M93C0797

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .